Guerbet SA, a global specialist in contrast agents and solutions for medical imaging, reported a revenue of €387.8 million for the first half of 2025, marking a decrease of 7.5% from the same period in 2024. The decline was attributed to a negative foreign exchange effect of €8.0 million, primarily due to fluctuations in Latin American currencies including the Brazilian real. On a constant exchange rate $(CER.UK)$ basis, the revenue was down 5.6%. The geographical breakdown indicated that sales in the EMEA region were €169.6 million, down 7.7% at CER, while the Americas experienced a slight decline of 0.3% at CER, with sales totaling €124.2 million. Asia saw a decrease of 7.3% at CER, with sales amounting to €100.5 million. Despite the decline in the first half, Guerbet SA remains optimistic about the second half of 2025, expecting double-digit growth driven by a favorable comparison base and normalization of activity in France. The company has confirmed its full-year targets, anticipating revenue growth of 3-5% at constant exchange rates and like-for-like, along with an increase in profitability. Guerbet projects a restated EBITDA margin of more than 15% and expects to achieve positive free cash flow for the year.